Search
Clearwater, FL Paid Clinical Trials
A listing of 182 clinical trials in Clearwater, FL actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
61 - 72 of 182
There are currently 182 clinical trials in Clearwater, Florida looking for participants to engage in research studies. Trials are conducted at various facilities, including Morton Plant Hospital, GSK Investigational Site, Clinical Research of West Florida, Inc and Clinical Research of West Florida. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Featured Trial
Paid Clinical Studies Nationwide
Recruiting
Nationwide clinical trials offered in your area. Some trials offering up to several thousand dollars in compensation for participation.
Featured Trial
Major Depressive Disorder Clinical Study
Recruiting
Is depression weighing you down? Local major depressive disorder clinical studies are now enrolling participants in the area. Participating in research studies helps contribute to the advancement of future medicine and treatment options. There is no obligation to take part and health insurance is not required.
Conditions:
Major Depressive Disorder
Major Depression
Major Depressive Episode
Major Depressive Disorder (MDD)
Major Depressive Disorders
Featured Trial
Atopic Dermatitis (Eczema) Study
Recruiting
The purpose of this clinical study is to see whether an investigational injectable medication can help to treat symptoms of moderate to severe Atopic Dermatitis (eczema). You may qualify to participate if you were diagnosed with Atopic Dermatitis at least 1 year ago and are currently experiencing symptoms. Participants who qualify for the study will receive trial-related procedures and study medication at no cost. The site staff can provide you with additional details.
Conditions:
Atopic Dermatitis
Dermatitis
Atopic
Atopic Dermatitis Eczema
Atopic Eczema
* Compensation for time may be available
Featured Trial
KALOS
Recruiting
The KALOS study is evaluating if a new type of inhaler called BGF MDI may provide benefit for people whose asthma symptoms are not fully controlled using their current inhaler treatment
Safety Study of CC-93538 in Adult and Adolescent Participants With Eosinophilic Esophagitis
Recruiting
This study is an open-label, uncontrolled study design to evaluate the long-term safety and tolerability of treatment with CC-93538. The study will enroll participants who participated in the CC-93538-EE-001 or CC-93538-DDI-001 studies.
Gender:
All
Ages:
Between 12 years and 75 years
Trial Updated:
03/29/2024
Locations: Gastro Florida, Clearwater, Florida
Conditions: Eosinophilic Esophagitis
A Single-ascending Dose (Part A) and Repeat-dose (Part B) Study to Investigate the Safety, Pharmacokinetics and Efficacy (Part B Only) of UCB1381 in Healthy Study Participants (Part A) and in Study Participants With Moderate to Severe Atopic Dermatitis (Part B)
Recruiting
The purpose of the study is to investigate the safety and tolerability of single-ascending doses of UCB1381 (intravenous and subcutaneous) in healthy study participants and after repeat intravenous dosing in study participants with atopic dermatitis. Efficacy will be assessed following repeat intravenous dosing versus placebo in study participants with atopic dermatitis.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
03/28/2024
Locations: Up0110 108, Clearwater, Florida
Conditions: Atopic Dermatitis
Study to evaLuate the effIcacy and Safety of abeLacimab in High-risk Patients With Atrial Fibrillation Who Have Been Deemed Unsuitable for Oral antiCoagulation (LILAC-TIMI 76)
Recruiting
A study to evaluate the effect of abelacimab relative to placebo on the rate of ischemic stroke or systemic embolism (SE) in patients with Atrial Fibrillation (AF) who have been deemed by their responsible physicians or by their own decision to be unsuitable for oral anticoagulation therapy.
Gender:
All
Ages:
65 years and above
Trial Updated:
03/28/2024
Locations: Anthos Investigative Site 1025, Clearwater, Florida +1 locations
Conditions: Atrial Fibrillation (AF)
Phase 2 Placebo-Controlled Study to Assess the Safety and Efficacy of ESK-001 in Active Systemic Lupus Erythematosus
Recruiting
The purpose of this study is to assess the clinical efficacy, safety, PK, and PD of multiple dose levels of ESK-001 compared with placebo in adult patients with SLE.
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
03/28/2024
Locations: Investigator Site #1045, Clearwater, Florida
Conditions: SLE
Induction Study #1 of Oral Ozanimod as Induction Therapy for Moderately to Severely Active Crohn's Disease
Recruiting
This is a study to explore the effect of oral ozanimod as an induction treatment for participants with moderately to severely active Crohn's Disease.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
03/27/2024
Locations: Local Institution - 062, Clearwater, Florida
Conditions: Crohn Disease
EVOLVE-MI: EVOLocumab Very Early After Myocardial Infarction
Recruiting
The primary objective of this study is to evaluate the effectiveness of early treatment with evolocumab plus routine lipid management vs routine lipid management alone when administered in the acute setting to reduce myocardial infarction, ischemic stroke, arterial revascularization, and all-cause death in subjects hospitalized for an acute myocardial infarction (non-ST-segment elevation myocardial infarction [NSTEMI] and ST-segment elevation myocardial infarction [STEMI]).
Gender:
All
Ages:
Between 18 years and 99 years
Trial Updated:
03/27/2024
Locations: Clearwater Cardiovascular Consultants, Clearwater, Florida
Conditions: Cardiovascular Disease, Myocardial Infarction, Stroke, Coronary Revascularization
An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease
Recruiting
This is an extension study to evaluate safety and efficacy of ozanimod in participants with moderately to severely active Crohn's Disease.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
03/27/2024
Locations: Gastro Florida, Clearwater, Florida +1 locations
Conditions: Crohn Disease
Phase 2 Study to Assess Efficacy & Safety of WP1302 Prevent Relapse of MMI w/Draw in Subj. w/ Graves' dz
Recruiting
This is a Phase 2, double-blind, placebo controlled, Methimazole (MMI) withdrawal study in subjects with Graves' disease. The study consists of up to 5 periods: a screening period of up to 2 weeks; a WP1302 or placebo titration with Methimazole period of 12 weeks; a Full dose of WP1302 or placebo with Methimazole tapering period of 26 weeks; a follow-up period of 4 weeks; and an extended follow-up period of 6 months.
After screening, eligible subjects will be randomized to treatment at a ratio... Read More
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
03/27/2024
Locations: BayCare Health System, Inc., Clearwater, Florida
Conditions: Graves Disease
Safety and Efficacy of Efavaleukin Alfa in Participants With Moderately to Severely Active Ulcerative Colitis
Recruiting
The main purpose of this study is to evaluate the effect of efavaleukin alfa on induction of clinical remission in participants with moderately to severely active ulcerative colitis (UC).
Participants will be randomized to receive 1 of 3 efavaleukin alfa doses or placebo during a 12-week induction period. Participants who complete the 12-week induction period will have the option to enter an exploratory long-term treatment period for up to 40 weeks (total of up to 52 weeks of treatment) if, in... Read More
Gender:
All
Ages:
Between 18 years and 80 years
Trial Updated:
03/27/2024
Locations: West Central Gastroenterology, Clearwater, Florida
Conditions: Ulcerative Colitis
ELACESTRANT in Women and Men With CDK4/6 Inhibitor-Naive Estrogen Receptor Positive, HER-2 Negative Metastatic Breast Cancer Study
Recruiting
The purpose of this study is to evaluate the efficacy and safety of elacestrant over the course of 6 months in patients with ER+/HER2- advanced/metastatic breast cancer who received no prior CDK4/6i in the metastatic setting.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/27/2024
Locations: Morton Plant Hospital - Baycare Health System, Clearwater, Florida
Conditions: Metastatic Breast Cancer
A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus
Recruiting
The purpose of this study is to evaluate the effectiveness and safety of deucravacitinib compared with placebo in an active moderate to severe Systemic Lupus Erythematosus (SLE) population.
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
03/27/2024
Locations: Local Institution - 0213, Clearwater, Florida
Conditions: Systemic Lupus Erythematosus
A Study to Test Asundexian for Preventing a Stroke Caused by a Clot in Participants After an Acute Ischemic Stroke or After a High-risk Transient Ischemic Attack, a So-called Mini Stroke
Recruiting
Researchers are looking for a better way to prevent an ischemic stroke which occurs when a blood clot travelled to the brain in people who within the last 72 hours had:
an acute stroke due to a blood clot that formed outside the heart (acute non-cardioembolic ischemic stroke), or
TIA/mini-stroke with a high risk of turning into a stroke (high-risk transient ischemic attack), and who are planned to receive standard of care therapy. Acute ischemic strokes or TIA/mini-stroke result from a blocked... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
03/26/2024
Locations: BayCare Health System | Morton Plant Hospital, Neuroscience Research department, Clearwater, Florida
Conditions: Prevention of Ischemic Stroke, Acute Non-cardioembolic Ischemic Stroke, High-risk Transient Ischemic Attack
61 - 72 of 182